These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 2167306)

  • 41. Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes.
    Andreasen PA; Sottrup-Jensen L; Kjøller L; Nykjaer A; Moestrup SK; Petersen CM; Gliemann J
    FEBS Lett; 1994 Feb; 338(3):239-45. PubMed ID: 8307187
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2.
    Thorsen S; Philips M; Selmer J; Lecander I; Astedt B
    Eur J Biochem; 1988 Jul; 175(1):33-9. PubMed ID: 3136015
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Structural determinants of the noncatalytic chain of tissue-type plasminogen activator that modulate its association rate with plasminogen activator inhibitor-1.
    de Serrano VS; Castellino FJ
    J Biol Chem; 1990 Jun; 265(18):10473-8. PubMed ID: 2113057
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1.
    Madison EL; Goldsmith EJ; Gerard RD; Gething MJ; Sambrook JF; Bassel-Duby RS
    Proc Natl Acad Sci U S A; 1990 May; 87(9):3530-3. PubMed ID: 2110366
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells.
    Mimuro J; Loskutoff DJ
    J Biol Chem; 1989 Mar; 264(9):5058-63. PubMed ID: 2494180
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human Co115 colon carcinoma cells potentiate the degradation of laminin mediated by tissue-type plasminogen activator.
    Tran-Thang C; Vouillamoz D; Kruithof EK; Sordat B
    J Cell Physiol; 1994 Nov; 161(2):285-92. PubMed ID: 7962113
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Functional characteristics of receptor-bound urokinase on human monocytes: catalytic efficiency and susceptibility to inactivation by plasminogen activator inhibitors.
    Kirchheimer JC; Remold HG
    Blood; 1989 Sep; 74(4):1396-402. PubMed ID: 2548640
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.
    Olson D; Pöllänen J; Høyer-Hansen G; Rønne E; Sakaguchi K; Wun TC; Appella E; Danø K; Blasi F
    J Biol Chem; 1992 May; 267(13):9129-33. PubMed ID: 1315748
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The majority of type 1 plasminogen activator inhibitor associated with cultured human endothelial cells is located under the cells and is accessible to solution-phase tissue-type plasminogen activator.
    Schleef RR; Podor TJ; Dunne E; Mimuro J; Loskutoff DJ
    J Cell Biol; 1990 Jan; 110(1):155-63. PubMed ID: 2104856
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Heparin enhances active site-dependent binding of tissue-type plasminogen activator to endothelial cells.
    Rosenfeld L; Kuo A; Hirsh J; Klugherz B; Gardell SJ; Cines DB; Barnathan ES
    Blood; 1992 Sep; 80(6):1486-95. PubMed ID: 1520875
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cell-specific regulation of plasminogen activator inhibitor 1 and tissue type plasminogen activator release by human kidney mesangial cells.
    Peraldi MN; Rondeau E; Medcalf RL; Hagège J; Lacave R; Delarue F; Schleuning WD; Sraer JD
    Biochim Biophys Acta; 1992 Apr; 1134(3):189-96. PubMed ID: 1558843
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Receptor binding and degradation of urokinase-type plasminogen activator by human mesangial cells.
    Nguyen G; Li XM; Peraldi MN; Zacharias U; Hagège J; Rondeau E; Sraer JD
    Kidney Int; 1994 Jul; 46(1):208-15. PubMed ID: 7933839
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The release of plasminogen activators (t-PA and u-PA) and plasminogen activator inhibitor (PAI-1) after venous stasis.
    Falkon L; Garí M; Borrell M; Fontcuberta J
    Blood Coagul Fibrinolysis; 1992 Feb; 3(1):33-8. PubMed ID: 1623118
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of interaction of active-site serine mutants of tissue-type plasminogen activator with plasminogen activator inhibitor-1.
    Monge JC; Lucore CL; Fry ET; Sobel BE; Billadello JJ
    J Biol Chem; 1989 Jun; 264(18):10922-5. PubMed ID: 2499585
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1.
    Cubellis MV; Wun TC; Blasi F
    EMBO J; 1990 Apr; 9(4):1079-85. PubMed ID: 2157592
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
    Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ
    J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ethanol-induced up-regulation of the urokinase receptor in cultured human endothelial cells.
    Tabengwa EM; Grenett HE; Benza RL; Abou-Agag LH; Tresnak JK; Wheeler CG; Booyse FM
    Alcohol Clin Exp Res; 2001 Feb; 25(2):163-70. PubMed ID: 11236828
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Progesterone stimulates degradation of urokinase plasminogen activator (u-PA) in endometrial stromal cells by increasing its inhibitor and surface expression of the u-PA receptor.
    Casslén B; Nordengren J; Gustavsson B; Nilbert M; Lund LR
    J Clin Endocrinol Metab; 1995 Sep; 80(9):2776-84. PubMed ID: 7673423
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential regulation of plasminogen activation in normal keratinocytes and SCC-4 cells by fibroblasts.
    Boxman IL; Quax PH; Löwik CW; Papapoulos SE; Verheijen J; Ponec M
    J Invest Dermatol; 1995 Mar; 104(3):374-8. PubMed ID: 7861005
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Binding of tissue plasminogen activator to human endothelial cells. Importance of the B-chain as a ligand.
    Cheng XF; Bäck O; Nilsson TK; Nylander Lundqvist E; Pohl G; Wallén P
    Biochem J; 1992 Oct; 287 ( Pt 2)(Pt 2):407-13. PubMed ID: 1332673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.